XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2017
Dec. 29, 2017
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Oct. 31, 2018
Apr. 30, 2018
Mar. 31, 2018
Sep. 30, 2015
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2018
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues                           $ 371,120 $ 1,327,274    
Grant funding liability                           4,975,484     $ 7,474,310
Advaccine | Customer Concentration Risk                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Accounts receivable                           0     7,100,000
Revenue under collaborative research and development arrangements                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues                           39,615 71,500    
Advaccine | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Upfront payment received                           3,000,000.0      
Additional revenue to be achieved                           108,000,000.0      
Collaboration Agreement, Payment Earned                           $ 2,000,000.0      
Royalty period                           10 years      
Period from effective date for termination                           1 year      
Revenues                                 5,000,000.0
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues                           $ 0     5,000,000.0
ApolloBio | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Upfront payment received                       $ 23,000,000.0   23,000,000.0   $ 23,000,000.0  
Additional revenue to be achieved                           $ 20,000,000.0      
Royalty period                           10 years      
Period from effective date for termination                           1 year      
Territory expansion option period   3 years                              
Proceeds received in upfront payment                       19,400,000          
Advisory fees                       960,000          
Number of days written notice before termination                           90 days      
ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Foreign corporate income taxes reducing upfront payment                       2,200,000          
Foreign non-corporate income taxes reducing upfront payment                       $ 1,400,000          
AstraZeneca                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues               $ 2,000,000.0 $ 2,000,000.0                
AstraZeneca | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Upfront payment received $ 27,500,000                       $ 27,500,000        
Anticipated development and regulatory event based payment receivable milestones                           $ 125,000,000      
Anticipated commercial event based payment receivable milestones                           115,000,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received       $ 6,900,000                          
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received                     $ 56,000,000            
Collaborative agreement, period to receive funding for research and development                     5 years            
Funding received for research and development                           2,400,000 1,100,000    
Grant funding liability                           251,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received           $ 9,000,000.0                      
Funding received for research and development                           2,400,000 2,400,000    
Grant funding liability                           4,000,000.0      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received       5,000,000.0                          
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received       $ 1,300,000                          
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Funding received for research and development         $ 5,000,000.0                 893,000 64,000    
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Funding received for research and development             $ 1,100,000     $ 2,200,000       0 $ 134,000    
Grant funding liability                           660,000      
Department of Defence | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contra-research and development expense                           7,800,000      
Accounts receivable                           $ 9,600,000     $ 11,400,000
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Funding received for research and development     $ 54,500,000                            
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Purchase price, procurement contract     $ 16,600,000